PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Tizanidine hydrochloride - Spasticity and muscle spasm
PAD Profile : Tizanidine hydrochloride - Spasticity and muscle spasm Important
Keywords :
spinal cord injury, MS, multiple sclerosis
Brand Names Include :
Tizagelan
Important Information :
Specialist to retain prescribing for first 4 months. Monitor liver function.
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 December 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network recommends the use of tizanidine for the treatment of spasticity.
Tizanidine will be considered BLUE (no information sheet) on the traffic light system.
Prescribing should be retained by the specialist until the patient has been stabilised on the optimal dose which must be a minimum of 4 months.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.02.02. Skeletal muscle relaxants